Jupiter Asset Management Ltd. Acquires 136,019 Shares of CareDx, Inc. $CDNA

Jupiter Asset Management Ltd. increased its holdings in shares of CareDx, Inc. (NASDAQ:CDNA) by 218.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 198,384 shares of the company’s stock after acquiring an additional 136,019 shares during the quarter. Jupiter Asset Management Ltd. owned about 0.36% of CareDx worth $3,876,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP acquired a new stake in shares of CareDx in the second quarter valued at approximately $40,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of CareDx by 7.8% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,082,308 shares of the company’s stock worth $21,148,000 after purchasing an additional 78,728 shares in the last quarter. Aviva PLC increased its position in shares of CareDx by 19.8% in the second quarter. Aviva PLC now owns 26,132 shares of the company’s stock worth $511,000 after purchasing an additional 4,317 shares during the period. First Eagle Investment Management LLC raised its stake in CareDx by 15.3% in the second quarter. First Eagle Investment Management LLC now owns 379,023 shares of the company’s stock valued at $7,406,000 after purchasing an additional 50,409 shares in the last quarter. Finally, Cetera Trust Company N.A lifted its position in CareDx by 11.2% during the second quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock worth $238,000 after purchasing an additional 1,225 shares during the period.

CareDx Stock Performance

Shares of CDNA opened at $15.87 on Friday. CareDx, Inc. has a 52 week low of $10.96 and a 52 week high of $26.37. The stock has a market capitalization of $816.24 million, a price-to-earnings ratio of 15.56 and a beta of 2.50. The stock has a fifty day moving average of $14.78 and a 200-day moving average of $15.55.

CareDx (NASDAQ:CDNA) last issued its earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.15. CareDx had a return on equity of 18.03% and a net margin of 17.97%.The business had revenue of $100.06 million during the quarter, compared to analysts’ expectations of $95.25 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. The business’s revenue for the quarter was up 20.7% compared to the same quarter last year. CareDx has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that CareDx, Inc. will post -0.9 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on CDNA. Zacks Research lowered shares of CareDx from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Wells Fargo & Company decreased their price objective on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Friday, August 8th. Craig Hallum lowered their price objective on shares of CareDx from $40.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, July 18th. William Blair began coverage on CareDx in a report on Tuesday, August 26th. They issued a “market perform” rating on the stock. Finally, Weiss Ratings raised CareDx from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CareDx currently has an average rating of “Hold” and an average target price of $26.00.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.